Given that small molecules make up more than 50% of the drug development pipeline, adopting a proactive non-clinical to clinical strategy is crucial for accelerating your program.
A holistic bioanalysis strategy that incorporates spatial analysis allows researchers to produce quality data, identify drug targets, evaluate efficacy, and optimize delivery. Join industry experts Troy Voelker and Corinne Ramos as they cover a step-by-step approach to a rugged method, including:
- Strategies moving from pre-clinical to clinical
- Spatial bioanalysis and moving into GLP
- Molecule stability and reproducibility
- Handling matrices and compounds
- Different instrumentation and uses
- Cold storage check list
- Ongoing use of ICH M-10
View our on-demand webinar to learn how to implement a comprehensive strategy that expedites the development of your small molecule.